[EN] 2-HALO-5-ALKYNYL-PYRIDYL NICOTINIC LIGANDS<br/>[FR] LIGANDS 2-HALO-5-ALCYNYL-PYRIDYLE NICOTINIQUES
申请人:UNIV GEORGETOWN
公开号:WO2014160783A1
公开(公告)日:2014-10-02
Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia.
揭示了一种对烟碱乙酰胆碱受体具有配体作用的杂环化合物。这些化合物可用于治疗患有一系列治疗适应症的哺乳动物,包括阿尔茨海默病、帕金森病、运动障碍、托瑞特综合征、精神分裂症、注意缺陷障碍、焦虑、疼痛、抑郁、强迫症、化学物质滥用、酗酒、记忆缺失、假性痴呆、甘瑟综合征、偏头痛、暴食症、肥胖症、经前综合征或晚期黄体期综合征、吸烟成瘾、创伤后综合征、社交恐惧症、慢性疲劳综合征、早泄、勃起困难、厌食症、睡眠障碍、自闭症、哑症、拔毛癖和低体温症。